文献速递产科

腹部赘肉抬高装置对剖宫产术后疼痛的影响:一项随机对照试验

Effect of panniculus elevation device on postoperative pain after cesarean delivery: a randomized controlled trial.
PubMed 文献 · Am J Obstet Gynecol MFM · 2023-03-06

该非盲前瞻性随机对照试验纳入278例剖宫产患者,随机分为腹部赘肉抬高装置组与无装置组,主要结局为产后总吗啡毫克当量使用量;装置组与对照组在总阿片类药物使用、其他阿片类药物指标及疼痛满意度上均无统计学显著差异,肥胖亚组趋势相似。

要点

  • 剖宫产术后使用腹部赘肉抬高装置未显著减少总阿片类药物使用量。
  • 装置组与对照组在住院及门诊阿片类药物使用、主观疼痛评分和疼痛干扰评分上无统计学显著差异。
  • 装置使用中位时间为5天(四分位距3-9),64%随机分配至装置组的参与者表示愿意再次使用。

核心结论

  • 剖宫产术后使用腹部赘肉抬高装置未显著减少患者总阿片类药物使用量。

研究设计与样本

  • 非盲前瞻性试验,纳入年龄≥18岁、剖宫产术后36小时内合格并知情同意的患者,随机分为腹部赘肉抬高装置组或无装置组。
  • 排除垂直皮肤切口或慢性阿片类药物使用障碍的患者。
  • 2021年4月至2022年7月筛查538例,484例合格,278例知情同意并随机化;56例(20%)失访,最终222例纳入分析(装置组118例 vs 对照组104例)。
  • 主要结局为产后总吗啡毫克当量使用量;次要结局包括住院和门诊阿片类药物使用、主观疼痛评分及患者报告结局测量信息系统疼痛干扰评分。
  • 对肥胖参与者(n=152)进行预先设定的亚组分析。

主要发现

  • 装置组与对照组的总阿片类药物使用量无统计学显著差异。
  • 其他阿片类药物使用指标及疼痛满意度结局在两组间无统计学显著差异。
  • 两组随访频率相似(P=.09)。
  • 装置使用中位时间为5天(四分位距3-9),64%随机分配至装置组的参与者表示愿意再次使用。
  • 肥胖参与者(n=152)中观察到相似趋势。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 56例参与者(20%)失访。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Suboptimal treatment of postpartum pain is associated with persistent pain and postpartum depression. Multimodal analgesia can achieve superior pain relief and decreased opioid consumption after surgery. There is limited and conflicting data on abdominal support devices to reduce postoperative pain and opioid use after cesarean delivery. OBJECTIVE: This study aimed to examine whether the use of a panniculus elevation device decreases opioid use and improves postoperative pain after cesarean delivery. STUDY DESIGN: This was an unblinded prospective trial in which eligible, consenting patients aged ≥18 years were randomized to the panniculus elevation device group or no device group within 36 hours after cesarean delivery. The device studied adheres to the abdomen and lifts the panniculus. Moreover, it can be repositioned during use. Patients with a vertical skin incision or chronic opioid use disorder were excluded. Participants were surveyed 10 and 14 days after delivery about opioid use and pain satisfaction. The primary outcome was total morphine milligram equivalents used after delivery. The secondary outcomes were inpatient and outpatient opioid use, subjective pain scores, and Patient-Reported Outcomes Measurement Information System pain interference scores. An a priori subgroup analysis was performed on participants with obesity who may uniquely benefit from panniculus elevation. RESULTS: Of 538 patients screened for inclusion from April 2021 to July 2022, 484 were eligible, and 278 were consented and randomized. Moreover, 56 participants (20%) were lost to follow-up, leaving 222 (118 in the device group vs 104 in the control group) for analysis. Follow-up frequency was similar between groups (P=.09). Demographic and clinical characteristics were similar between groups. There was no statistically significant difference in total opioid use, other opioid use measures, or pain satisfaction outcomes. Median device use was 5 days (interquartile range, 3-9), and 64% of participants randomized to device use stated that they would use it again. Here, similar trends were observed among participants with obesity (n=152). CONCLUSION: The use of a panniculus elevation device did not significantly reduce total opioid use after cesarean delivery in patients.

来源:Am J Obstet Gynecol MFM,查看原文。版权归原作者所有。

引用

  1. Zuckerwise LC, Mulhall JC, Thompson JL, et al. Effect of panniculus elevation device on postoperative pain after cesarean delivery: a randomized controlled trial. Am J Obstet Gynecol MFM. 2023. PMID: 36889439. doi:10.1016/j.ajogmf.2023.100920

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。